Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
- Resource Type
- Article
- Source
- In
Lung Cancer August 2023 182 - Subject
- Language
- ISSN
- 0169-5002